Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Rare Disease Day 2021: Rare Is Many. Rare Is Strong. Rare Is Proud.

February 23, 2021

Alnylam Pharmaceuticals

What is it like living with a rare disease? The experiences are as varied as the diseases themselves and as unique as the people affected. More than 300 million people worldwide are diagnosed with a rare condition, but there is so much more that defines them than being a patient.

Rare Disease Day, celebrated annually on the last day of February, was created to bring attention to the different experiences of people living with rare diseases and to remind healthcare professionals (HCPs), policymakers and the general public of the challenges this community faces. These challenges include delays in diagnoses, lack of familiarity with certain conditions among HCPs and the community at large, barriers to access/quality care and, often, significant financial and emotional burdens.

While some aspects of living with a rare disease are similar, there is no singular shared experience. There is, however, a common sentiment among those impacted that their disease does not define them. The following perspectives highlight the diverse backgrounds, interests, hobbies and talents of people living with three rare diseases — acute hepatic porphyria (AHP), hereditary transthyretin-mediated (hATTR) amyloidosis and primary hyperoxaluria type 1 (PH1) — and prove that “Rare Is Many. Rare Is Strong. Rare Is Proud.”

You may think the rarest thing about me is AHP, but you’d be surprised to know something even rarer. I was a world-class figure skater!

– Nicole, living with AHP

 
You may think the rarest thing about me is PH1, but you’d be surprised to know something even rarer. I climbed two 14,000-foot mountain peaks in one day less than one year after receiving a kidney/liver double transplant.

– John, diagnosed with PH1

 
You may think the rarest thing about me is hATTR amyloidosis, but you’d be surprised to know something even rarer. For nearly two decades, every September, I would spend three days riding my bicycle over 250 miles from Boston to New York City.

– Rick, living with hATTR amyloidosis

 
You may think the rarest thing about me is AHP, but you’d be surprised to know something even rarer. I compete in virtual car races against some of the biggest names in racing.

– Sean, living with AHP

 
You may think the rarest thing about my daughter is that she has PH1, but you’d be surprised to know something even rarer. She is seven years old and loves practicing taekwondo.

– Laura, caregiver of a child diagnosed with PH1

 
You may think the rarest thing about me is AHP, but you’d be surprised to know something even rarer. I was part of an elite dance group, and even danced with a celebrity!

– Candace, living with AHP

 
You may think the rarest thing about me is hATTR amyloidosis, but you’d be surprised to know something even rarer. I write poetry and hope to have my first collection published by June 2021. I also play bodhrán and guitar.

– Rosaline, living with hATTR amyloidosis

 
You may think the rarest thing about me is PH1, but you’d be surprised to know something even rarer. I powered through a whole season of high school softball while harboring a large and painful kidney stone.

– Mayah, diagnosed with PH1

 
You may think the rarest thing about me is AHP, but you’d be surprised to know something even rarer. I learned how to play the violin again nine months after experiencing an episode of complete paralysis.

– Agnes, living with AHP

 
You may think the rarest thing about me is hATTR amyloidosis, but you’d be surprised to know something even rarer. I’ve swum 3.5km or more several times during events like Odyssée Massalia 2019 or Cap Naio 2016 despite having a pacemaker.

– Jean-Christophe, living with hATTR amyloidosis

 

For more information about Rare Disease Day 2021 and to find out how you can get involved, visit rarediseaseday.org.

To learn more about the rare disease community in the U.S. and worldwide, check out organizations like NORD, EURORDIS and Global Genes.

Tags

Patient Focus, Articles, Rare Disease Day, Patient Advocacy, Patient Stories

Related Content See All News ›
Patient Focus Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyr ...
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Patient Focus Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyr ...
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site